trending Market Intelligence /marketintelligence/en/news-insights/trending/A-51PmRDEl_-Zk_XvOnsTA2 content esgSubNav
In This List

Dimerix to raise A$2M for the development of orphan drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dimerix to raise A$2M for the development of orphan drug

Dimerix Ltd. is looking to raise A$2 million to fund the development of DMX-200 as a potential treatment of chronic kidney disease.

The company said it received commitments for 333,333,333 new shares at 0.6 Australian cent apiece, with closing expected Feb. 4.

Westar Capital Ltd. acted as lead manager to the offer.

As of Jan. 24, US$1 was equivalent to A$1.32.